Associated hereditary cancer. A pathogenic or likely pathogenic variant associated with an increased risk of colon cancer was found in the POLE gene.
POLE
DNA variants in the POLE gene are associated with a higher lifetime risk of adenomatous polyps and colon cancer, and possibly additional cancers, often with an earlier age of onset
than the general population.
Advancing Bladder Cancer Detection
The current gold standard for bladder cancer detection is cystoscopy
Exploring the Challenges
Cystoscopy is a painful and invasive procedure
Limitations
Confirmatory tests such as a CT scan, intravenous, pyelogram (IVP), X-ray, MRI, ultrasound, and urine cytology are also used but with limited utility
Diagnostic testing of this gene is recommended to identify a potential genetic basis for a condition. This type of testing can inform prognosis and clinical care for a symptomatic patient or be used to screen unaffected patients (including family members) for increased genetic risk for the condition. Selecting the diagnostic gene product will affect how the test is ordered, including billing information (e.g., the reason for testing and ICD10 codes), how the report is formatted, and follow-up testing options for family members.

Sensitive and Specific
The URO17 Urine test has 100% sensitivity
& 96% specificity.*
Compatible
Works with all standard immunohistochemistry systems, and detects high grade and low grade bladder cancer
Gold Standard Potential
Testing suggests that the URO17 test could improve the accuracy of cytology and cystoscopy in monitoring recurrence cases, and detection of new cases in patients with hematuria
How URO17 Compares with other Popular Urine Tests for Bladder Cancer
Sensitivity
Specificity
Cytology
NMP22
CX Bladder
UroVysion
Cystoscopy
56%
79%
82%
69%
98%
96%
84%
85%
78%
94%
URO17
*Babu et. al., Modern Pathology, 2019 May; 32(5):717-724
100%
96%
Order sample report